Psylocybina (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Psylocybina" in Polish language version.

refsWebsite
Global rank Polish rank
2nd place
6th place
4th place
7th place
7,025th place
low place
924th place
75th place
149th place
235th place
3,887th place
1,274th place
1st place
1st place
117th place
278th place
5,712th place
low place
5th place
2nd place
low place
low place

doi.org

dx.doi.org

  • Jeffrey K. Aronson, Plant Poisons and Traditional Medicines, [w:] Manson’s Tropical Infectious Diseases, wyd. 23, Elsevier, 2014, 1128–1150.e6, DOI10.1016/b978-0-7020-5101-2.00077-7, ISBN 978-0-7020-5101-2 (ang.).
  • Marie-Laure Espiard i inni, Hallucinogen persisting perception disorder after psilocybin consumption: a case study, „European Psychiatry: The Journal of the Association of European Psychiatrists”, 20 (5-6), 2005, s. 458–460, DOI10.1016/j.eurpsy.2005.04.008, PMID15963699 [dostęp 2023-01-26] (ang.).
  • David J. Nutt i inni, Drug harms in the UK: a multicriteria decision analysis, „The Lancet”, 376 (9752), 2010, s. 1558–1565, DOI10.1016/S0140-6736(10)61462-6, PMID21036393 [dostęp 2023-01-26] (ang.).
  • A. Dasgupta, Challenges in Laboratory Detection of Unusual Substance Abuse: Issues with Magic Mushroom, Peyote Cactus, Khat, and Solvent Abuse, „Advances in Clinical Chemistry”, 78, 2017, s. 163–186, DOI10.1016/bs.acc.2016.07.004, PMID28057187 [dostęp 2023-01-26] (ang.).
  • Kunio Gonmori, Naofumi Yoshioka, The examination of mushroom poisonings at Akita University, „Legal Medicine (Tokyo, Japan)”, 5 Suppl. 1, 2003, S83–S86, DOI10.1016/s1344-6223(02)00127-x, PMID12935559 [dostęp 2023-01-26] (ang.).
  • Robert S. Gable, Comparison of acute lethal toxicity of commonly abused psychoactive substances, „Addiction (Abingdon, England)”, 99 (6), 2004, s. 686–696, DOI10.1111/j.1360-0443.2004.00744.x, PMID15139867 [dostęp 2023-01-26] (ang.).
  • T.H. Lim, C.A. Wasywich, P.N. Ruygrok, A fatal case of 'magic mushroom' ingestion in a heart transplant recipient, „Internal Medicine Journal”, 42 (11), 2012, s. 1268–1269, DOI10.1111/j.1445-5994.2012.02955.x, PMID23157524 [dostęp 2023-01-26] (ang.).
  • A. Horita, L.J. Weber, Dephosphorylation of psilocybin to psilocin by alkaline phosphatase, „Proceedings of the Society for Experimental Biology and Medicine”, 106, 1961, s. 32–34, DOI10.3181/00379727-106-26228, PMID13715851 [dostęp 2023-01-26] (ang.).
  • Ricardo Jorge Dinis-Oliveira, Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance, „Drug Metabolism Reviews”, 49 (1), 2017, s. 84–91, DOI10.1080/03602532.2016.1278228, PMID28074670 [dostęp 2023-01-26] (ang.).
  • Robin L. Carhart-Harris i inni, Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms, „Scientific Reports”, 7 (1), 2017, DOI10.1038/s41598-017-13282-7, PMID29030624, PMCIDPMC5640601 (ang.).
  • Matthew W. Johnson, Albert Garcia-Romeu, Roland R. Griffiths, Long-term follow-up of psilocybin-facilitated smoking cessation, „The American Journal of Drug and Alcohol Abuse”, 43 (1), 2017, s. 55–60, DOI10.3109/00952990.2016.1170135, ISSN 1097-9891, PMID27441452, PMCIDPMC5641975 [dostęp 2023-02-04].
  • Michael P. Bogenschutz i inni, Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial, „JAMA Psychiatry”, 79 (10), 2022, s. 953, DOI10.1001/jamapsychiatry.2022.2096, PMID36001306, PMCIDPMC9403854 (ang.).

erowid.org

hopkinsmedicine.org

imperial.ac.uk

www3.imperial.ac.uk

msn.com

msnbc.msn.com

nih.gov

ncbi.nlm.nih.gov

  • Marie-Laure Espiard i inni, Hallucinogen persisting perception disorder after psilocybin consumption: a case study, „European Psychiatry: The Journal of the Association of European Psychiatrists”, 20 (5-6), 2005, s. 458–460, DOI10.1016/j.eurpsy.2005.04.008, PMID15963699 [dostęp 2023-01-26] (ang.).
  • David J. Nutt i inni, Drug harms in the UK: a multicriteria decision analysis, „The Lancet”, 376 (9752), 2010, s. 1558–1565, DOI10.1016/S0140-6736(10)61462-6, PMID21036393 [dostęp 2023-01-26] (ang.).
  • A. Dasgupta, Challenges in Laboratory Detection of Unusual Substance Abuse: Issues with Magic Mushroom, Peyote Cactus, Khat, and Solvent Abuse, „Advances in Clinical Chemistry”, 78, 2017, s. 163–186, DOI10.1016/bs.acc.2016.07.004, PMID28057187 [dostęp 2023-01-26] (ang.).
  • Kunio Gonmori, Naofumi Yoshioka, The examination of mushroom poisonings at Akita University, „Legal Medicine (Tokyo, Japan)”, 5 Suppl. 1, 2003, S83–S86, DOI10.1016/s1344-6223(02)00127-x, PMID12935559 [dostęp 2023-01-26] (ang.).
  • Robert S. Gable, Comparison of acute lethal toxicity of commonly abused psychoactive substances, „Addiction (Abingdon, England)”, 99 (6), 2004, s. 686–696, DOI10.1111/j.1360-0443.2004.00744.x, PMID15139867 [dostęp 2023-01-26] (ang.).
  • T.H. Lim, C.A. Wasywich, P.N. Ruygrok, A fatal case of 'magic mushroom' ingestion in a heart transplant recipient, „Internal Medicine Journal”, 42 (11), 2012, s. 1268–1269, DOI10.1111/j.1445-5994.2012.02955.x, PMID23157524 [dostęp 2023-01-26] (ang.).
  • A. Horita, L.J. Weber, Dephosphorylation of psilocybin to psilocin by alkaline phosphatase, „Proceedings of the Society for Experimental Biology and Medicine”, 106, 1961, s. 32–34, DOI10.3181/00379727-106-26228, PMID13715851 [dostęp 2023-01-26] (ang.).
  • Ricardo Jorge Dinis-Oliveira, Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance, „Drug Metabolism Reviews”, 49 (1), 2017, s. 84–91, DOI10.1080/03602532.2016.1278228, PMID28074670 [dostęp 2023-01-26] (ang.).
  • Robin L. Carhart-Harris i inni, Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms, „Scientific Reports”, 7 (1), 2017, DOI10.1038/s41598-017-13282-7, PMID29030624, PMCIDPMC5640601 (ang.).
  • Matthew W. Johnson, Albert Garcia-Romeu, Roland R. Griffiths, Long-term follow-up of psilocybin-facilitated smoking cessation, „The American Journal of Drug and Alcohol Abuse”, 43 (1), 2017, s. 55–60, DOI10.3109/00952990.2016.1170135, ISSN 1097-9891, PMID27441452, PMCIDPMC5641975 [dostęp 2023-02-04].
  • Michael P. Bogenschutz i inni, Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial, „JAMA Psychiatry”, 79 (10), 2022, s. 953, DOI10.1001/jamapsychiatry.2022.2096, PMID36001306, PMCIDPMC9403854 (ang.).

pubmed.ncbi.nlm.nih.gov

scienceblog.co.uk

sciencedirect.com

  • Psilocybin. [w:] ScienceDirect Topics [on-line]. Elsevier. [dostęp 2018-09-19]. (ang.).

sigmaaldrich.com

web.archive.org

worldcat.org